Compare SKYX & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYX | CNTB |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.3M | 135.7M |
| IPO Year | 2014 | 2020 |
| Metric | SKYX | CNTB |
|---|---|---|
| Price | $1.05 | $1.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $5.00 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 1.5M | 214.9K |
| Earning Date | 05-13-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.11 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,700,948.00 | $64,000.00 |
| Revenue This Year | $25.12 | N/A |
| Revenue Next Year | $24.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.78 | N/A |
| 52 Week Low | $0.96 | $0.99 |
| 52 Week High | $3.29 | $3.82 |
| Indicator | SKYX | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 34.85 |
| Support Level | $1.02 | $1.46 |
| Resistance Level | $1.31 | $2.05 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 24.24 | 5.22 |
SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. Its technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post, and is capable of feeding electric power to an appliance. It generates its income from lighting and heating products sold in the USA.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.